生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

交易中 08-28 14:25:00

5,443.986

-91.133

-1.65%

最高5,538.509	最低5,436.167	成交量1.67亿
今开5,533.704	昨收5,535.119	日振幅1.85%
总市值0.00	流通市值0.00	总股本0.00
成交额50.86亿	换手率--	流通股本0.00
市净率5.8698	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5443.986,"timestamp":1787898300670,"preClose":5535.119,"halted":0,"volume":167391381,"delay":0,"changeRate":-0.016465,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-91.133301,"latestTime":"08-28 14:25:00","open":5533.7036,"high":5538.509,"low":5436.1665,"amount":5086103373,"amplitude":0.01849,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787904600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787880600000,1787889600000],[1787893200000,1787904000000]],"pbRate":5.8698,"peRate":196.615329,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161/tweets","defaultTab":"tweets","newsList":[{"id":"2662705611","title":"郭广昌：复星围绕医药等核心业务轨道，保持高强度科创投入，上半年科创投入42亿增16.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705611","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662705611?lang=zh_cn&edition=full","pubTime":"2026-08-28 13:04","pubTimestamp":1787893440,"startTime":"0","endTime":"0","summary":"未来，复星将聚焦优势产业，在稳定增长轨道上加速发展。根据8月27日晚公布的业绩报告，复星国际上半年总收入达869.6亿元人民币，归属于母公司股东的利润为17.2亿元，同比飙升160.3%。创新投入方面，复星上半年科创投入达42亿元，同比增长16.7%，主要聚焦医药等核心业务。郭广昌表示，复星已构建起植根中国、面向全球的整合式创新能力，未来将凭借不断增强的人才与产业厚度，持续提升全球竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-28/doc-inipvvzv4675007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09939","BK1161","00656","159938","BK1515","159982","BK1230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662056325","title":"麦科医药－Ｂ(02335.HK)中期亏损约2.32亿元 同比增加364.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662056325","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662056325?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:47","pubTimestamp":1787892424,"startTime":"0","endTime":"0","summary":"格隆汇8月28日丨麦科医药－Ｂ(02335.HK)发布截至2026年6月30日止六个月中期业绩。于报告期内，集团录得期内亏损约人民币2.32亿元，同比增加364.3%。集团的经调整亏损净额约为人民币1.12亿元，较2025年同期增加128.5%。该增加乃主要归因于研发活动的投资增加。集团录得经营活动所得现金净额约人民币1.09亿元，而2025年同期则为经营活动所用现金净额约人民币5230万元，实现了从经营现金流出净额到经营现金流入净额的转变。此乃主要归因于收到来自云顶新耀的预付款人民币2亿元。基本每股亏损0.88元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260828/32351515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662305521","title":"麦科医药-B(02335.HK)发布中期业绩 股东应占亏损2.31亿元 同比扩大372.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662305521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662305521?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:30","pubTimestamp":1787891448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179480337","title":"陕西麦科医药科技股份有限公司——2026年上半年亏损2.317亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1179480337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179480337?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:18","pubTimestamp":1787890689,"startTime":"0","endTime":"0","summary":"陕西麦科医药科技股份有限公司（麦科医药-B）公布了截至2026年6月30日的六个月财务报告。数据显示，该公司在此期间录得亏损人民币2.317亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109370447","title":"映恩生物-B携手基因泰克，基于DUPAC新型载荷平台共研下一代抗体偶联药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1109370447","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109370447?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:10","pubTimestamp":1787890236,"startTime":"0","endTime":"0","summary":"映恩生物-B近日宣布，已与罗氏旗下基因泰克达成一项全球合作与许可协议。双方将依托映恩生物自主研发的DUPAC创新载荷平台，共同推进新一代抗体偶联药物的研发工作。这一合作标志着映恩生物在ADC领域的创新实力获得国际制药巨头的认可。映恩生物此次与基因泰克的联手，不仅为其技术平台提供了国际化验证机会，也为公司未来管线拓展奠定了坚实基础。随着更多类似合作的落地，国内ADC药物研发水平有望迈上新台阶。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","LU2543165471.USD","09606","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662053254","title":"映恩生物-B午前涨近6% 与罗氏集团旗下Genentech签署合作许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2662053254","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662053254?lang=zh_cn&edition=full","pubTime":"2026-08-28 11:49","pubTimestamp":1787888940,"startTime":"0","endTime":"0","summary":"映恩生物与罗氏集团旗下Genentech签署合作许可协议，依托公司DUPAC平台开发多款肿瘤适应症下一代ADC药物。Genentech将获得合作所产生的ADC的全球独家许可，并于第1a期临床开发完成后，Genentech将独自承担进一步临床开发及商业化的责任。根据合作协议，映恩生物将收取4500万美元的首付款，并有资格就所有合作项目收取总额超过10亿美元的潜在开发、监管及商业化里程碑付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-28/doc-inipvvzv8928555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","HK0000252160.HKD","09606","HK0000500386.USD","LU2543165471.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662805333","title":"港股异动丨康方生物跌超6% 中期收入及毛利不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662805333","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662805333?lang=zh_cn&edition=full","pubTime":"2026-08-28 11:07","pubTimestamp":1787886421,"startTime":"0","endTime":"0","summary":"康方生物跌超6%，报94.75港元。康方生物公布截至6月底止中期业绩，股东应占亏损4.24亿元，去年同期亏损5.7亿元，每股亏损46分，不派息。期内，总收入18.06亿元，同比增27.92%；毛利13.4亿元，上升19.6%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/28/20260828841762.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/28/20260828841762.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260828/32351350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","LU0417516902.SGD","LU0348784397.USD","LU0561508036.HKD","KCAI","LU1794554557.SGD","LU2399975544.HKD","LU2476274308.USD","LU0417516571.SGD","LU0540923850.HKD","BK1161","LU1720050803.USD","LU0348766576.USD","LU2778985437.USD","IE00B5MMRT66.SGD","LU0348827113.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU2476274720.SGD","IE00B543WZ88.USD","LU0634319403.HKD","LU2488822045.USD","BK4588","LU0348767384.USD","LU0348735423.USD","VXUS","LU0348783233.USD","BK4585","LU0417516738.SGD","KURE","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662305899","title":"港股异动 | 映恩生物-B(09606.HK)早盘涨超5% 与Genentech订立ADC合作 潜在里程碑金额超10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662305899","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662305899?lang=zh_cn&edition=full","pubTime":"2026-08-28 10:35","pubTimestamp":1787884530,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","HK0000252152.HKD","LU2543165471.USD","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662583930","title":"同源康(02410)1类新药氘申艾替尼片获批附条件上市，为EGFR突变肺癌脑转移临床治疗带来新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2662583930","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662583930?lang=zh_cn&edition=full","pubTime":"2026-08-28 10:27","pubTimestamp":1787884074,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年8月27日，港股创新药企同源康医药宣布，公司自主研发的1类新药甲磺酸氘申艾替尼片已获得中国国家药品监督管理局批准附条件上市，用于具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02410","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037097","title":"同源康医药-B早盘高开近15% 创新药TY-9591片获批准附条件上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037097","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037097?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:35","pubTimestamp":1787880900,"startTime":"0","endTime":"0","summary":"模拟交易客户端同源康医药-B早盘高开近15%，截至发稿，股价上涨14.99%，现报7.825港元，成交额275.83万港元。8月27日晚，同源康医药公布，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已获得中国国家药品监督管理局批准附条件上市，适应症为具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-28/doc-inipvrtx8899235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","02410","06978","BK1161","IBBQ","BK1574","09939","BK1515","MEDX","159938","IPOS","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037219","title":"股市必读：卫信康新发布《西藏卫信康医药股份有限公司2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037219","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037219?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:29","pubTimestamp":1787880599,"startTime":"0","endTime":"0","summary":"公司公告汇总西藏卫信康医药股份有限公司2026年半年度报告摘要截至2026年6月30日，公司总资产1,964,655,715.41元，较上年度末增长5.24%；归属于上市公司股东的净资产1,540,807,617.81元，较上年度末增长4.36%。西藏卫信康医药股份有限公司关于召开2026年半年度业绩说明会的公告公司定于2026年9月4日15:00–16:00通过上证路演中心以网络互动方式召开2026年半年度业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800017047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK1161","159938","603676","09939","BK1515","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037468","title":"港股异动 | 同源康医药-B(02410.HK)高开近15% 创新药TY-9591片获批准附条件上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037468?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:24","pubTimestamp":1787880257,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","BK1574","BK1161","02410","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662882037","title":"港股公告掘金 | 蜜雪集团上半年实现收入约152.16亿元 同比增长2.3% 全球门店网络持续扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2662882037","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662882037?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:05","pubTimestamp":1787879123,"startTime":"0","endTime":"0","summary":"重大事项：和黄医药(00013)：爱领达(凡瑞格拉替尼)获中国国家药监局批准用于治疗FGFR2融合/重排的肝内胆管癌患者映恩生物-B(09606)与Genentech订立全球研发合作及许可协议 以基于公司DUPAC新型有效载荷平台开发下一代ADC石四药集团(02005)已取得国家药监局有关钆布醇注射液(7.5ml：4.5354g)的药品生产注册批件固生堂(02273)：收购YC TCM (TAMA","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09606","BK1219","VXUS","LU2460026573.USD","BK1233","HK0000252160.HKD","HK0000252152.HKD","02097","BK1191","BK4585","00013","BK4588","BK1588","BK1616","LU2543165471.USD","02005","02273","KCAI","HK0000500386.USD","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662032725","title":"国家医保局召开医保促进“十五五”医药产业高质量发展座谈会","url":"https://stock-news.laohu8.com/highlight/detail?id=2662032725","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662032725?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:00","pubTimestamp":1787878842,"startTime":"0","endTime":"0","summary":"加大对创新药械和创新服务项目的支持","market":"sh","thumbnail":"https://img3.gelonghui.com/5a971-e4bc2669-8728-40d1-b85b-174c38b13f1a.jpg?guru_height=2595&guru_width=4630&guru_size=776778","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/5a971-e4bc2669-8728-40d1-b85b-174c38b13f1a.jpg?guru_height=2595&guru_width=4630&guru_size=776778"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6376571","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["MEDX","BK1574","LNGR","IBBQ","09939","BK1161","06978","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662032938","title":"瑞博生物-B(06938) 2026年中期业绩：全球合作推动收入增长，核心管线与平台价值持续兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2662032938","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662032938?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:44","pubTimestamp":1787877873,"startTime":"0","endTime":"0","summary":"8月27日，瑞博生物-B 2026年中期业绩正式出炉。业绩改善主要得益于全球合作项目相关许可收入的确认及合作里程碑的持续推进。与此同时，公司继续保持对核心临床管线及创新递送平台的研发投入。实际上，上述只是瑞博生物创新平台价值兑现的一个缩影。8月21日，恒生指数系列季检结果公布，瑞博生物正式获纳入恒生综合指数成分股，后续将符合沪港通及深港通下的港股通股票的调入标准，今年9月7日起正式生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034757","title":"迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034757","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034757?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:25","pubTimestamp":1787876738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年8月27日重新向香港联合交易所有限公司(以下简称“香港联交所”)递交了发行H股股票并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请材料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","159938","BK1574","688192","09939","BK0239","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034349","title":"映恩生物-B(09606)与Genentech订立全球研发合作及许可协议 以基于公司DUPAC新型有效载荷平台开发下一代ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034349","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034349?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:58","pubTimestamp":1787875127,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B 发布公告，于2026年8月27日，本公司与罗氏集团成员公司Genentech, Inc.订立合作及许可协议，以基于本公司专有的映恩独特有效载荷抗体偶联平台开发针对若干肿瘤适应症的下一代抗体偶联药物。Genentech将获得合作所产生的ADC的全球独家许可，并于第1a期临床开发完成后，Genentech将独自承担进一步临床开发及商业化的责任。DUPAC涵盖多种有效载荷，包括DUP5、DUP9及DUP10，每种均通过独特的抗肿瘤机制发挥作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B(09606)与Genentech订立全球研发合作及许可协议 以基于公司DUPAC新型有效载荷平台开发下一代ADC","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606","BK1161","HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034833","title":"新股消息 | 迪哲医药(688192.SH)再度递表港交所 舒沃哲®已在中国内地上市并在美国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034833?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:51","pubTimestamp":1787874703,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1515","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137704341","title":"映恩生物-B（Dualitybio-B）达成合作协议，将获4500万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1137704341","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137704341?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:21","pubTimestamp":1787872884,"startTime":"0","endTime":"0","summary":"映恩生物-B（Dualitybio-B）近日宣布，根据一项新签署的合作协议，公司将获得一笔高达4500万美元的首期付款。这一里程碑式的进展，不仅彰显了公司在生物医药领域的创新实力，也为其后续研发管线注入了强劲动力。协议的达成，标志着映恩生物-B在对外合作战略上迈出了坚实一步，有望进一步加速其候选药物的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","BK1161","09606","HK0000252160.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133605867","title":"映恩生物-B与基因泰克达成全球研发合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1133605867","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133605867?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:20","pubTimestamp":1787872833,"startTime":"0","endTime":"0","summary":"映恩生物-B宣布，已与基因泰克签署一项全球研究、开发合作及许可协议。此举标志着双方在生物医药领域的深度携手，为创新疗法的研发注入了新的动力。协议涵盖的范围广泛，旨在共同推进相关项目的临床前与临床阶段研究，并赋予基因泰克在全球范围内的商业化权利。这一合作不仅彰显了映恩生物-B在抗体药物偶联物等前沿技术领域的研发实力，也为其国际化战略迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09606","HK0000252152.HKD","HK0000252160.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0101},{"period":"3month","weight":0.0152},{"period":"6month","weight":-0.04},{"period":"1year","weight":0.0144},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}